Dans les pipelines : AstraZeneca, Sanofi, Lilly

2023-10-27 07:00:00

European Marketing Authorization for Enhertu

L’get stronger (trastuzumab deruxtecan) developed by AstraZeneca et Daiichi Sankyo has just obtained European Marketing Authorization. This ADC (antibody drug conjugate) is now authorized as monotherapy in Europe, for patients suffering from metastatic non-small cell lung cancer with HER2 mutation and treated with at least one line of therapy. In Europe, Enhertu is already approved against certain forms of breast cancer and stomach cancer.

Positive phase II results for Sanofi

Sanofi presented new phase IIb data from its amlitelimab in atopic dermatitis. The monoclonal antibody significantly improved the symptoms of the disease, with a 61.5% reduction in the average EASI score, an index used to measure eczema. Furthermore, the compound could be the best-in-class drug for the treatment of atopic dermatitis. Sanofi hopes to start phase III in the first half of 2024.

VOS INDICES

source

Criteria met against Crohn’s for Lilly

In its phase III trial, the mirikizumaba monoclonal antibody developed by Eli Lilly, met all of its endpoints for the treatment of adults with moderately to severely active Crohn’s disease. Over the course of one year, patients treated with this drug candidate demonstrated clinical remission and endoscopic response. The laboratory hopes to file a regulatory application with the FDA during 2024.

Selected for you